Fundación Instituto Valenciano de Oncología

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.3K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

<i>TERT</i> Promoter Mutations in Familial and Sporadic Melanoma

Susanne Horn, Adina Figl, P. Sivaramakrishna Rachakonda et al. · Science · 2013 · 1.8K citations

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

M. Bolla, Laurence Collette, L.E.C.M. Blank et al. · The Lancet · 2002 · 1.7K citations

Urology, Genitourinary Cancer, Medicine +6

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.2K citations

Noah Trial, Breast Oncology, Oncology +7